Randomized phase III study of exatecan and gemcitabine compared with gemcitabine alone in untreated advanced pancreatic cancer. - Wikidata - wikimedia - TriplyDB

Randomized phase III study of exatecan and gemcitabine compared with gemcitabine alone in untreated advanced pancreatic cancer.

Randomized phase III study of exatecan and gemcitabine compared with gemcitabine alone in untreated advanced pancreatic cancer.

http://www.wikidata.org/entity/Q33372697

about

Recent progress in pancreatic cancer Novel agents for advanced pancreatic cancer Albumin-bound paclitaxel in solid tumors: clinical development and future directions Imaging and Therapy of Pancreatic Cancer with Phosphatidylserine-Targeted Nanovesicles Systemic treatment for inoperable pancreatic adenocarcinoma: review and update Systemic therapies for pancreatic cancer--the role of pharmacogenetics Pancreatic cancer treatment and research: an international expert panel discussion.Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine Biweekly triple combination chemotherapy with gemcitabine, oxaliplatin, levofolinic acid and 5-fluorouracil (GOLF) is a safe and active treatment for patients with inoperable pancreatic cancer.Meta-analyses of chemotherapy for locally advanced and metastatic pancreatic cancer: results of secondary end points analyses.A Phase II Trial of Gemcitabine plus Capecitabine for Patients with Advanced Pancreatic Cancer Does gemcitabine-based combination therapy improve the prognosis of unresectable pancreatic cancer?Dose modification and efficacy of nab-paclitaxel plus gemcitabine vs. gemcitabine for patients with metastatic pancreatic cancer: phase III MPACT trial.Gemcitabine in Combination with a Second Cytotoxic Agent in the First-Line Treatment of Locally Advanced or Metastatic Pancreatic Cancer: a Systematic Review and Meta-Analysis.Efficacy and Toxicity of Different Chemotherapy Regimens in the Treatment of Advanced or Metastatic Pancreatic Cancer: A Network Meta-Analysis.Comparative effectiveness and resource utilization of nab-paclitaxel plus gemcitabine vs FOLFIRINOX or gemcitabine for the first-line treatment of metastatic pancreatic adenocarcinoma in a US community setting Pancreatic cancer: pathobiology, treatment options, and drug delivery.Targeting the Epidermal Growth Factor Receptor in Addition to Chemotherapy in Patients with Advanced Pancreatic Cancer: A Systematic Review and Meta-Analysis Allogeneic granulocyte macrophage colony-stimulating factor-secreting tumor immunotherapy alone or in sequence with cyclophosphamide for metastatic pancreatic cancer: a pilot study of safety, feasibility, and immune activation.Chemotherapy regimens for advanced pancreatic cancer: a systematic review and network meta-analysis.Chemoradiotherapy in pancreatic carcinoma.Screening for pancreatic cancer: why, how, and who?A six-gene signature predicts survival of patients with localized pancreatic ductal adenocarcinoma.Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the Cancer and Leukemia Group B (CALGB 80303).Current and emerging therapies for the treatment of pancreatic cancer.Combination 5-fluorouracil, folinic acid and cisplatin (LV5FU2-CDDP) followed by gemcitabine or the reverse sequence in metastatic pancreatic cancer: final results of a randomised strategic phase III trial (FFCD 0301).Antitumor activity of emodin against pancreatic cancer depends on its dual role: promotion of apoptosis and suppression of angiogenesis Phase I/II clinical trial using HLA-A24-restricted peptide vaccine derived from KIF20A for patients with advanced pancreatic cancer A meta-analysis of gemcitabine containing chemotherapy for locally advanced and metastatic pancreatic adenocarcinoma.Systemic therapy for metastatic pancreatic adenocarcinoma.Redox-responsive targeted gelatin nanoparticles for delivery of combination wt-p53 expressing plasmid DNA and gemcitabine in the treatment of pancreatic cancer.Current immunotherapeutic approaches in pancreatic cancer.Enhanced antitumor efficacy of gemcitabine by evodiamine on pancreatic cancer via regulating PI3K/Akt pathway.Effect of thalidomide in combination with gemcitabine on human pancreatic carcinoma SW-1990 cell lines in vitro and in vivo.Second-line therapy for gemcitabine-pretreated advanced or metastatic pancreatic cancer.Multidisciplinary neoadjuvant management for potentially curable pancreatic cancer.Metastatic Pancreatic Cancer: American Society of Clinical Oncology Clinical Practice Guideline Efficacy and safety of gemcitabine plus erlotinib for locally advanced or metastatic pancreatic cancer: a systematic review and meta-analysis.Efficacy and safety profile of nab-paclitaxel plus gemcitabine in patients with metastatic pancreatic cancer treated to disease progression: a subanalysis from a phase 3 trial (MPACT).Transarterial chemoembolization with/without cryotherapy is associated with improved clinical outcomes of sorafenib for the treatment of advanced hepatocellular carcinoma

P2860

Q24626346-7D31C225-DBAA-4C0A-B7F9-ABC212B8ACAE Q26787087-797E1927-DC08-4D0E-B079-9FA68CA5BBD5 Q26798674-72177BCC-1505-4A7A-AC95-5FEB3D928AED Q26828959-C0B97535-7D01-47A1-9DDE-D4724BC9AC41 Q26830913-B5D441AE-D515-4FC6-8E06-970D1122D8D0 Q27021716-7CE16A51-CECC-4A37-B0D7-92F259160461 Q27690868-53EB9B26-09E9-4377-9119-75169D497693 Q29616728-1545A41A-1FC6-410F-B246-E86270CB9C14 Q33378968-74213770-796B-435E-B784-0B24D4B9862C Q33380084-7AC7490C-256B-4D6B-890C-E1FA0BBA4CB7 Q33402374-F004480F-A01A-4EC9-9E40-30830EA98DA0 Q33403498-E4A1CB9C-063D-499F-8BAF-126A46634985 Q33432931-4726BE8B-F7B8-424B-BE15-551C206082D6 Q33440500-1C9EB17C-01B2-4E03-AFA5-617A517ABF8A Q33442676-E786EFFE-3E4B-477C-B4DA-5F5EAD4B3475 Q33615072-D12F2966-697F-4969-9D58-0E39373587EB Q33749460-8B149D89-2BC2-48C5-BDE9-D04D4EBC59C6 Q33754779-CCDC2EEE-B35C-42C6-8269-C223085BEA74 Q33887648-643001AF-E81B-4590-A8FF-D1EC8D4BA40B Q33898080-FD7EFA86-4DE7-475B-84B7-3E45EBBE59CC Q33914136-89625FC9-5C11-4EA9-B0B1-33444A2ED52D Q33959412-79FD2D2E-0094-4220-862C-4CC1C703DA4C Q33992146-5392A515-8466-4035-A567-2C2C67B155A8 Q34049260-F0B5DE05-A1CD-4B2A-9BD3-EC226A760011 Q34129346-8076317B-1310-4D6E-8050-950C0BB858CA Q34308370-81B4E6DA-3E54-42C4-9CB7-78C9999ABD86 Q34372558-A9B642C9-E8A1-45BD-8388-766D0B1ECE1E Q34478149-47AF5C2D-3C31-4160-A13A-CA15D3CDF5C7 Q34818494-4946BDBD-FDE5-4883-9E45-4243ABBF1665 Q35076238-36151AE2-AC54-40E8-8FC1-7FC9B390FF9D Q35089242-3AC3BC59-9B22-4499-B5D3-9F96B82567BD Q35212837-452AE89F-C489-4D14-B48D-F9C99D295C9C Q35578720-3EC93A0F-B7CE-47D6-AD04-D4BAFE72D230 Q35742237-465ACD07-27DD-434A-A6E2-8BAA9C292640 Q35872109-00292184-635F-413D-9CD9-D48149001CC3 Q36023889-EE0DCA30-244C-4575-B378-9175978880BF Q36035888-07CDAB81-44DE-496A-9D38-B37F34E5735B Q36064511-BF52565B-1440-4E96-87CB-8C31282EB1C4 Q36171310-01305F41-9F82-4339-B0D7-6739C965F93B Q36285672-078BEDB2-A41D-48A9-95B0-D3226F03A5EC

P2860

Randomized phase III study of exatecan and gemcitabine compared with gemcitabine alone in untreated advanced pancreatic cancer.

http://www.wikidata.org/entity/Q33372697

description

2006 nî lūn-bûn

@nan

2006 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած

@hyw

2006 թվականի սեպտեմբերին հրատարակված գիտական հոդված

@hy

2006年の論文

@ja

2006年論文

@yue

2006年論文

@zh-hant

2006年論文

@zh-hk

2006年論文

@zh-mo

2006年論文

@zh-tw

2006年论文

@wuu

name

Randomized phase III study of ...... ed advanced pancreatic cancer.

@ast

Randomized phase III study of ...... ed advanced pancreatic cancer.

@en

type

label

Randomized phase III study of ...... ed advanced pancreatic cancer.

@ast

Randomized phase III study of ...... ed advanced pancreatic cancer.

@en

prefLabel

Randomized phase III study of ...... ed advanced pancreatic cancer.

@ast

Randomized phase III study of ...... ed advanced pancreatic cancer.

@en

P1433

Q33372697-7D496646-346D-4CEE-9E4F-16D7F3B2373D

P1476

Q33372697-B570C834-3E3A-4E7E-BB13-F1C79C5B49D5

P2093

Q33372697-0218F250-4379-4445-BB91-8ABE2DFAB712

Q33372697-1942CE6E-8314-4617-9DB7-F298E0375616

Q33372697-30AB3602-21BD-42BA-B731-37B4FCDC1EE0

Q33372697-33616C93-028E-4D78-9170-F66F07ADB492

Q33372697-3A0A3948-D29A-450F-96ED-99CE1617A3A0

Q33372697-73DA094E-0359-47B0-B80E-370FA88D7DD1

Q33372697-B2FF64B7-8F1D-4EC8-AC42-21CCFBFE683E

Q33372697-B4D9EA30-B131-4973-B522-422E58B3ACA2

Q33372697-C4FD7F9C-D712-4054-8673-2D45AF7FEFD5

Q33372697-F5C23EEE-5B1E-48FB-A9A7-22B3BC0D33C3

P304

Q33372697-EBCEEF24-C2EA-41F7-836F-4A25DB8A4D9F

P31

Q33372697-FE70BFF0-C15F-4E66-9931-541AC32C11A7

P356

Q33372697-D38C708A-DD4A-4481-AE70-5A720DC15578

P407

Q33372697-84B5552D-2929-4295-A87F-ADEA30002745

P433

Q33372697-473E429C-9B32-463E-8778-830C1482DD24

P478

Q33372697-DFFEAD55-584D-4F27-91D0-356BF04C5865

P50

Q33372697-629AD559-172A-45DC-BBC4-B20D9A371822

P577

Q33372697-EC324321-55D0-4BD8-A439-4E7BF28214A7

P698

Q33372697-2A2BF2D4-9418-4B53-AD98-DBC7A34ACC9C

P356

JCO.2006.07.0201

P1433

Journal of Clinical Oncology

P1476

Randomized phase III study of ...... ed advanced pancreatic cancer.

@en

P2093

Ghassan K Abou-Alfa

http://www.w3.org/2001/XMLSchema#string

Graydon Harker

http://www.w3.org/2001/XMLSchema#string

Herbert Hurwitz

http://www.w3.org/2001/XMLSchema#string

Judie Ackerman

http://www.w3.org/2001/XMLSchema#string

Kevie Feit

http://www.w3.org/2001/XMLSchema#string

Manuel Modiano

http://www.w3.org/2001/XMLSchema#string

Nerses Simon Tchekmedyian

http://www.w3.org/2001/XMLSchema#string

Richard Letourneau

http://www.w3.org/2001/XMLSchema#string

Robert L De Jager

http://www.w3.org/2001/XMLSchema#string

S Gail Eckhardt

http://www.w3.org/2001/XMLSchema#string

P304

4441-4447

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1200/JCO.2006.07.0201

http://www.w3.org/2001/XMLSchema#string

P407

P433

27

http://www.w3.org/2001/XMLSchema#string

P478

24

http://www.w3.org/2001/XMLSchema#string

P50

Eileen M O'Reilly

P577

2006-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

16983112

http://www.w3.org/2001/XMLSchema#string